27.50
+3.19%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BRIM Biotechnology
Its shares trade on Taiwan Stock Exchange under the ticker 6885.TW. It has been listed since 23 June 2022. In the fiscal year to 31 December 2023, it reported revenue of TWD 90,000 and a net loss of TWD 688.0m. At that date it held total assets of TWD 1.78bn and shareholders' equity of TWD 1.74bn.
BRIM Biotechnology, Inc. engages in the research and development of treatment drugs. The company is headquartered in Taipei City, Taipei. The company went IPO on 2022-06-23. The firm's product line is based on the pigment epithelium-derived factor (PEDF) and its derived short-chain polypeptide technology platform for multiple therapeutic areas and indications. The firm has four product candidates, BRM421 Dry Eye, BRM423 Severe Corneal Injury, BRM424 Neurotrophic Keratitis and BRM521 Degenerative Arthritis. BRM421 is primarily indicated for the treatment and repair of dry eye disease (DES) with corneal damage.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Jun 2022
- Website
- brimbiotech.com ↗
Leadership
Pay as last reported
- Qun LinChairman of the Board, since 2023
- Ms. Haishan JianVice Chairman of the Board, Chief Strategy Officer, since 2023
- Ms. Mei-Hui KuoChief Operating Officer
- Zhengwen LinChief Technology Officer
- Wen-Chyi ShyuGeneral Manager
- Jiani YanDeputy General Manager-Finance & Accounting, Head of Finance & Accounting, Corporate Governance Officer
- Mr. Wen-Chi LeeChief Strategy Officer, Chief Research & Development Officer, since 2023
- Ms. Sophia ChengDirector
- Chengzhi LiDirector
- Yixin LiDirector
- Huijin ZengDirector
- Shouzhen ChengIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- BRM421 Dry Eye treatment targets corneal damage in dry eye disease with PEDF technology.
- BRM423 Severe Corneal Injury uses PEDF-derived polypeptides for corneal repair.
- BRM424 Neurotrophic Keratitis leverages PEDF platform for nerve-related eye conditions.
Weaknesses
- BRM521 Degenerative Arthritis product candidate is in early development stages.
- Taipei City headquarters limits global market access for BRIM Biotechnology.
- Four product candidates face regulatory hurdles in multiple therapeutic areas.
Opportunities
- PEDF technology platform expands into new therapeutic areas beyond current indications.
- Taiwan's Biotechnology sector growth supports BRIM's R&D initiatives.
- BRM421 Dry Eye treatment targets a large patient population in Asia.
Threats
- PEDF-derived polypeptide technology faces competition from established ophthalmic drugs.
- Regulatory delays in Taiwan could impact BRIM's product development timeline.
- Global Biotechnology sector volatility affects funding for early-stage R&D.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.